Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may spot lingering lung cancer after surgery

NCT ID NCT05165160

Knowledge-focused Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether a blood test measuring DNA fragments can detect leftover cancer after lung cancer surgery. Researchers followed 133 patients with early-stage lung cancer for one year after their operation. The goal was to see if changes in the DNA test could predict if the cancer would come back.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple blood test to detect leftover cancer after surgery, helping doctors decide who needs more treatment.
What could go wrong
This is an observational study, not a treatment trial. The blood test may not reliably predict relapse, and results may not apply to all lung cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

133 people

The number who actually took part.

Started

Feb 2022

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age: 18 years or older * Patients with a resectable NSCLC * Definite stage I to IIIA * Performance status of 0, 1 or 2 * Normal end organ functions * Written and signed informed consent form * Subjects must be covered by public health insurance. Exclusion Criteria: * Any previous systemic neoadjuvant treatment: targeted therapy, chemotherapy, immune checkpoint blockade * Previous radiotherapeutic neoadjuvant treatment * Resection margins R1 and R2 * Non-invasive lung carcinoma * Multiple primary lung cancer. * Previous malignancy during the past 3 years (except non-melanomatous skin cancer) * Preexisting interstitial lung disease * known HIV, active viral B hepatitis or C hepatitis * Patient with any other situation responsible for cirDNA rate increasing (active auto-immune disease, 10 days following blood transfusion) * Patient unable to attend all scheduled visits * Woman of childbearing age without efficient contraception, breastfeeding * Patient with a legal protection measure (guardianship, curatorship) * Vulnerable patient protected by law

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC

Contacts and locations

Locations

  • University Hospital

    Montpellier, 34295, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.